These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16874013)

  • 1. Low-dose metronomic chemotherapy: myth or truth?
    Baruchel S; Stempak D
    Onkologie; 2006 Jul; 29(7):305-7. PubMed ID: 16874013
    [No Abstract]   [Full Text] [Related]  

  • 2. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
    André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
    Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can a rational design for metronomic chemotherapy dosing be devised?
    Maraveyas A; Lam T; Hetherington JW; Greenman J
    Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302
    [No Abstract]   [Full Text] [Related]  

  • 4. The importance of dose intensity in the outcome of chemotherapy.
    Hryniuk WM
    Important Adv Oncol; 1988; ():121-41. PubMed ID: 3042601
    [No Abstract]   [Full Text] [Related]  

  • 5. Relative dose intensity: improving cancer treatment and outcomes.
    Lenhart C
    Oncol Nurs Forum; 2005 Jul; 32(4):757-64. PubMed ID: 15990905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy: teaching old drugs new tricks?
    Vogelzang N
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence-based chemotherapy administration in advanced ovarian cancer: an impressive past, a disquieting present and an uncertain future.
    Markman M
    Gynecol Oncol; 2008 Apr; 109(1):4-7. PubMed ID: 18234303
    [No Abstract]   [Full Text] [Related]  

  • 8. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting the right dose in cancer chemotherapy--time to stop using surface area?
    Newell DR
    Br J Cancer; 2002 Apr; 86(8):1207-8. PubMed ID: 11953873
    [No Abstract]   [Full Text] [Related]  

  • 12. [Response to metronomic chemotherapy in a metastatic adenoid cystic carcinoma of the parotid gland].
    Visa L; Caballero M; Grau JJ
    Acta Otorrinolaringol Esp; 2010; 61(6):452-4. PubMed ID: 20152955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical application of drug dosing schedules in cancer therapy--Part II.
    Reich SD
    Cancer Nurs; 1984 Feb; 7(1):59-61. PubMed ID: 6559098
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of cell kinetics in cancer chemotherapy.
    Valeriote FA; Edelstein MB
    Semin Oncol; 1977 Jun; 4(2):217-26. PubMed ID: 327554
    [No Abstract]   [Full Text] [Related]  

  • 15. [Methods for optimizing cytostatic drug therapy].
    Lipp HP
    Med Monatsschr Pharm; 1995 Oct; 18(10):282-91. PubMed ID: 7476654
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
    Hanauske AR
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. X chemotherapy, myth and realities.
    Thomas M; Pavithran K
    J Indian Med Assoc; 2005 Sep; 103(9):489-90, 492, 494. PubMed ID: 16493871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcome with dose-dense chemotherapy.
    Keith B; Hall R; Scholnik A
    J Clin Oncol; 2004 Feb; 22(4):749; author rpely 751-3. PubMed ID: 14966104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.